Andere talen XOMA Corporation Nasdaq

Aandelen

XOMAO

US98419J4040

Beurs gesloten - Nasdaq Andere beurzen 22:30:01 17-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
25,1 ^USD	0,00%		0,00%	-0,08%

09/05	XOMA Corporation rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI
30/04	XOMA Corporation (NasdaqGM:XOMA) heeft de overname van drie First-in-Category Assets van Daré Bioscience, Inc. (NasdaqCM:DARE) voor $22 miljoen afgerond.	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ	14/05
Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	09/05
Xoma: Q1 Earnings Snapshot	09/05
XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities	09/05
XOMA : 2024 Letter to Shareholders	09/05
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%	30/04
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	30/04
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	25/04
XOMA : Acquisition/Asset Disposal - Form 8-K	03/04
XOMA Corporation Announces Closing of Tender Offer	03/04
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	03/04
XOMA Declares Quarterly Preferred Stock Dividends	21/03
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	19/03
Xoma: Q4 Earnings Snapshot	08/03
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	08/03
XOMA to Present at Upcoming Investor Conferences in March	28/02
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	19/02
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	16/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen XOMA Corporation Nasdaq

Aandelen

XOMAO

US98419J4040

Andere talen

Filters